Literature DB >> 33628225

Clinical Features of False-Negative Early Gastric Cancers: A Retrospective Study of Endoscopic Submucosal Dissection Cases.

Kohei Oka1, Naoto Iwai1,2, Takashi Okuda1, Tasuku Hara1, Yutaka Inada2, Toshifumi Tsuji1, Toshiyuki Komaki1, Junichi Sakagami1, Yuji Naito2, Keizo Kagawa1, Yoshito Itoh2.   

Abstract

BACKGROUND: We frequently encounter early gastric cancer (EGC) that could not be detected in the previous esophagogastroduodenoscopy even if the procedure was annually performed. However, little evidence exists regarding the characteristics of false-negative EGCs. Our aim was to reveal the clinical features of false-negative EGCs.
METHODS: We retrospectively reviewed cases of endoscopic submucosal dissection (ESD) for EGCs in Fukuchiyama City Hospital between January 2013 and May 2019. False-negative EGCs were defined as EGCs within 3 years of negative endoscopy. We evaluated the clinical characteristics of false-negative and initially detected EGCs and the difference in the detected and last missed endoscopy in false-negative EGCs. The miss rates of false-negative EGCs were compared between trainees (nonboard-certified endoscopists) and experienced endoscopists (board-certified endoscopists); thereafter, the characteristics of false-negative EGCs missed by trainees were investigated.
RESULTS: Of 219 cases, 119 were classified as false-negative EGCs. False-negative EGCs were characterized as smaller lesions, which presented with normal color or gastritis-like appearance, and were diagnosed after ESD and H. pylori eradication (P < 0.01). The rate of trainees in the last missed endoscopy was significantly higher than that in the detected endoscopy. The miss rate of false-negative EGC by trainees was higher than that of experienced endoscopists but not significantly different (0.70% vs. 0.57%, P = 0.08). The false-negative EGCs missed by trainees were characterized as reddish or well-differentiated lesions, which were located in the lower or lesser curvature of the stomach (P < 0.05).
CONCLUSION: The characteristics of false-negative EGCs were similar to those of H. pylori-eradicated EGC. Procedures with shortened examination time and those performed by trainees were risk factors of missing false-negative EGCs. Trainees should pay attention to reddish or well-differentiated EGCs located in the lower or lesser curvature of the stomach.
Copyright © 2021 Kohei Oka et al.

Entities:  

Year:  2021        PMID: 33628225      PMCID: PMC7886521          DOI: 10.1155/2021/6635704

Source DB:  PubMed          Journal:  Gastroenterol Res Pract        ISSN: 1687-6121            Impact factor:   2.260


  31 in total

1.  Mechanisms producing color change in flat early gastric cancers.

Authors:  U Honmyo; A Misumi; A Murakami; S Mizumoto; I Yoshinaka; M Maeda; S Yamamoto; S Shimada
Journal:  Endoscopy       Date:  1997-06       Impact factor: 10.093

2.  Difference in accuracy between gastroscopy and colonoscopy for detection of cancer.

Authors:  Osamu Hosokawa; Masakazu Hattori; Kenji Douden; Hiroyuki Hayashi; Kouji Ohta; Yasuharu Kaizaki
Journal:  Hepatogastroenterology       Date:  2007-03

3.  Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees.

Authors:  Takuji Kawamura; Hironori Wada; Naokuni Sakiyama; Yuki Ueda; Atsushi Shirakawa; Yusuke Okada; Kasumi Sanada; Kojiro Nakase; Koichiro Mandai; Azumi Suzuki; Mai Kamaguchi; Atsuhiro Morita; Kenichi Nishioji; Kiyohito Tanaka; Naomi Mochizuki; Koji Uno; Isao Yokota; Masao Kobayashi; Kenjiro Yasuda
Journal:  Dig Endosc       Date:  2017-02-10       Impact factor: 7.559

4.  Risk factors of developing interval early gastric cancer after negative endoscopy.

Authors:  Young Sin Cho; Il-Kwun Chung; Ji Hyun Kim; Yunho Jung; Tae Hoon Lee; Sang-Heum Park; Sun-Joo Kim
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

5.  Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradication therapy.

Authors:  Akiko Saka; Kazuyoshi Yagi; Satoshi Nimura
Journal:  Gastric Cancer       Date:  2015-03-10       Impact factor: 7.370

6.  Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study.

Authors:  Z Suvakovic; M G Bramble; R Jones; C Wilson; N Idle; J Ryott
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

7.  Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer.

Authors:  Yasumasa Ezoe; Manabu Muto; Noriya Uedo; Hisashi Doyama; Kenshi Yao; Ichiro Oda; Kazuhiro Kaneko; Yoshiro Kawahara; Chizu Yokoi; Yasushi Sugiura; Hideki Ishikawa; Yoji Takeuchi; Yoshibumi Kaneko; Yutaka Saito
Journal:  Gastroenterology       Date:  2011-08-19       Impact factor: 22.682

8.  Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study.

Authors:  Yuzo Sakai; Reiko Eto; Junji Kasanuki; Fukuo Kondo; Kazuki Kato; Makoto Arai; Takuto Suzuki; Michiko Kobayashi; Tomoaki Matsumura; Dan Bekku; Kenichi Ito; Shingo Nakamoto; Takeshi Tanaka; Osamu Yokosuka
Journal:  Gastrointest Endosc       Date:  2008-06-17       Impact factor: 9.427

9.  Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer.

Authors:  Toshiaki Hirasawa; Takuji Gotoda; Satoshi Miyata; You Kato; Tadakazu Shimoda; Hirokazu Taniguchi; Junko Fujisaki; Takeshi Sano; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

10.  Gastric superficial neoplasia: high miss rate but slow progression.

Authors:  Yuichi Shimodate; Motowo Mizuno; Akira Doi; Naoyuki Nishimura; Hirokazu Mouri; Kazuhiro Matsueda; Hiroshi Yamamoto
Journal:  Endosc Int Open       Date:  2017-08-07
View more
  1 in total

Review 1.  Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer.

Authors:  Darina Kohoutova; Matthew Banks; Jan Bures
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.